Skip to content
The Nexus
DossierENTITY

Paul Belcher

Coverage of Paul Belcher in the Nexus archive.

Earliest in view: Jul 16 · 00:00 UTCMost recent: Jul 16 · 00:00 UTC
Co-mentioned in this coverage
Cytivaorganization1Henrik Ihreperson1Artificial Intelligencetopic1drug purificationtopic1chromatography resintopic1bioreactorstopic1
Recent coverage
  • SCIENCEJul 16 · 00:00 UTCNEW SCIENTIST
    Drug discovery Is changing. Drug development must change too.

    Artificial intelligence and big data are accelerating drug discovery, creating a mismatch with existing manufacturing capabilities for safe mass production. Experts from Cytiva highlight challenges in scaling purification processes from lab to industrial scales, emphasizing the risks and complexities in translating promising drug candidates to market-ready therapies.

Paul Belcher · Dossier · The Nexus